Myeloid leukemia accelerated phase

MeSH D015465 - myeloid leukemia accelerated phase

Favorite

Competitive Landscape

Events Timeline

Commercial

Clinical Trials

Competitive landscape

See list view

D015464:Bcr-abl positive chronic myelogenous leukemia

47 Companies

13 Drugs

Success rate

D015465:

Myeloid leukemia accelerated phase

2 Companies

1 Drug

Success rate

Events Timeline

Commercial

Company Name	Drug Name	Trade Name	Patent Expires	Approval Date	Revenue	Period
Novartis	Nilotinib	Tasigna	2023-07-04	2007-10-29	$1,943 M	Q2/21-Q2/24

Clinical Trials

Historical Success Rate

Phase 1

84%

26/31

Phase 2

0/41

Phase 3

50%

1/2

Approved: 1Overall Success rate: 0%

All Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Company name

Phase 1

Phase 2

Phase 3

Phase 4

Drug Name